Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study.
atrial fibrillation
bleeding risk
diabetes mellitus
direct oral anticoagulants
edoxaban
stroke prevention
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
27 May 2020
27 May 2020
Historique:
received:
24
04
2020
revised:
20
05
2020
accepted:
22
05
2020
entrez:
31
5
2020
pubmed:
31
5
2020
medline:
31
5
2020
Statut:
epublish
Résumé
Diabetes mellitus (DM) is a chronic metabolic disease which is independently associated with unfavorable clinical outcomes in patients with atrial fibrillation (AF). Few real-world data are available about the clinical performance of non-vitamin K oral anticoagulants (NOACs) among patients with atrial fibrillation and diabetes. The aim of our propensity score-matched cohort study was to compare the safety and effectiveness of Edoxaban versus well-controlled vitamin K antagonists (VKAs) therapy among this population. In this study, we considered patients with AF and diabetes on Edoxaban or VKAs therapy included in the multicenter Atrial Fibrillation Research Database (NCT03760874). The occurrence of major bleedings (MB) and thromboembolic events (a composite of ischemic stroke, transient ischemic attack, systemic embolism) was respectively considered primary safety and effectiveness outcome. We identified 557 AF patients with diabetes who received Edoxaban (
Identifiants
pubmed: 32471222
pii: jcm9061621
doi: 10.3390/jcm9061621
pmc: PMC7356851
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Circ Arrhythm Electrophysiol. 2019 May;12(5):e007030
pubmed: 30995869
Diabetes Care. 2004 May;27(5):1047-53
pubmed: 15111519
J Am Heart Assoc. 2016 Feb 23;5(2):
pubmed: 26908401
Ann Intern Med. 2009 Sep 1;151(5):297-305
pubmed: 19721017
Diabetes Care. 1993 Aug;16(8):1137-45
pubmed: 8375244
J Am Coll Cardiol. 2017 Sep 12;70(11):1325-1335
pubmed: 28882229
Eur Heart J. 2009 May;30(9):1128-35
pubmed: 19282274
Clin Ther. 2019 Aug;41(8):1598-1604
pubmed: 31151813
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
JAMA Cardiol. 2017 Apr 1;2(4):442-448
pubmed: 28122078
J Am Coll Cardiol. 2017 Jan 31;69(4):409-419
pubmed: 28126158
Diabetes Metab Res Rev. 2017 Mar;33(3):
pubmed: 28029216
Diabet Med. 2018 Aug;35(8):1105-1110
pubmed: 29663521
J Thromb Haemost. 2015 Nov;13(11):2119-26
pubmed: 26764429
Cardiovasc Diabetol. 2018 Aug 31;17(1):121
pubmed: 30170601
Thromb Haemost. 2018 Jan;118(1):72-81
pubmed: 29304527
Stroke. 2015 Aug;46(8):2168-74
pubmed: 26152296
Vascul Pharmacol. 2011 Mar-Jun;54(3-6):68-74
pubmed: 21453786
Neurol Clin. 2000 May;18(2):309-19
pubmed: 10757828
Stroke. 2004 Oct;35(10):2362-7
pubmed: 15331796
Int J Cardiol. 2020 Apr 1;304:185-191
pubmed: 32008850
Europace. 2016 Nov;18(11):1609-1678
pubmed: 27567465
Thromb Res. 1992 Sep 15;67(6):643-54
pubmed: 1440530
G Ital Cardiol (Rome). 2017 Mar;18(3):199-207
pubmed: 28398378
Eur J Prev Cardiol. 2016 Apr;23(6):621-7
pubmed: 26254188
J Thromb Haemost. 2005 Dec;3(12):2811-3
pubmed: 16359522